CD52 and melanoma: CD5-2 treatment significantly enhanced the effectiveness of anti-PD1 antibody, both in the anti-PD1-sensitive MC38 tumors but also in the B16F10 melanoma model, which is classically insensitive to anti-PD1 treatment (12).